Portage Biotech Inc. (NASDAQ:PRTG – Get Rating) – Cantor Fitzgerald issued their FY2023 EPS estimates for Portage Biotech in a note issued to investors on Monday, June 6th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($0.60) per share for the year.
A number of other analysts also recently issued reports on the company. Zacks Investment Research downgraded Portage Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, June 1st. HC Wainwright initiated coverage on Portage Biotech in a research report on Monday, March 7th. They issued a “buy” rating and a $32.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $28.65.
A number of hedge funds and other institutional investors have recently made changes to their positions in PRTG. Morgan Stanley acquired a new position in Portage Biotech during the first quarter worth approximately $225,000. Bank of America Corp DE bought a new stake in shares of Portage Biotech during the second quarter worth approximately $38,000. Millennium Management LLC bought a new stake in shares of Portage Biotech during the second quarter worth approximately $245,000. BlackRock Inc. boosted its holdings in shares of Portage Biotech by 19.7% during the third quarter. BlackRock Inc. now owns 213,123 shares of the company’s stock worth $4,331,000 after acquiring an additional 35,096 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Portage Biotech by 30.2% during the third quarter. Geode Capital Management LLC now owns 45,629 shares of the company’s stock worth $927,000 after acquiring an additional 10,590 shares during the period. 4.57% of the stock is currently owned by hedge funds and other institutional investors.
About Portage Biotech (Get Rating)
Portage Biotech Inc, together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury.
- Get a free copy of the StockNews.com research report on Portage Biotech (PRTG)
- Now’s The Time To Buy MongoDB (NASDAQ: MDB)
- Chargepoint’s Stock Could Benefit from High Energy Prices
- Is It Too Late For Energy Stocks?
- MarketBeat Podcast: Get Your Mindset Right To Invest In The Current Market
- It’s Time To Get Interested In Ethereum Again
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.